Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Deffered Revenue: 2020-2022

Historic Non-Current Deffered Revenue for Xeris Biopharma Holdings (XERS) over the last 1 years, with Sep 2022 value amounting to $6.6 million.

  • Xeris Biopharma Holdings' Non-Current Deffered Revenue fell 2.65% to $6.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $6.6 million, marking a year-over-year decrease of 2.65%. This contributed to the annual value of $6.9 million for FY2021, which is 3.83% up from last year.
  • Xeris Biopharma Holdings' Non-Current Deffered Revenue amounted to $6.6 million in Q3 2022, which was down 2.27% from $6.8 million recorded in Q2 2022.
  • In the past 5 years, Xeris Biopharma Holdings' Non-Current Deffered Revenue registered a high of $6.9 million during Q1 2022, and its lowest value of $6.6 million during Q4 2020.
  • For the 3-year period, Xeris Biopharma Holdings' Non-Current Deffered Revenue averaged around $6.8 million, with its median value being $6.8 million (2021).
  • In the last 5 years, Xeris Biopharma Holdings' Non-Current Deffered Revenue rose by 3.83% in 2021 and then fell by 2.65% in 2022.
  • Xeris Biopharma Holdings' Non-Current Deffered Revenue (Quarterly) stood at $6.6 million in 2020, then climbed by 3.83% to $6.9 million in 2021, then dropped by 2.65% to $6.6 million in 2022.
  • Its last three reported values are $6.6 million in Q3 2022, $6.8 million for Q2 2022, and $6.9 million during Q1 2022.